GLUC Glucose Health, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1420108 · Fiscal year ends 12/31
Financial factors as of 2017-09-30 (2017Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-70.6%
TTM net income YoY73.8%
TTM EPS YoY—
Revenue 3-yr CAGR237.6%
Net income 3-yr CAGR—
Margins
Gross margin65.4%
Operating margin-36.8%
Net margin-96.5%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-241.9%
ROIC (approx.)—
Asset turnover2.51x
Leverage & solvency
Liabilities / assets1,717.4%
Debt / equity—
Current ratio0.06x
Interest coverage-0.29x
Cash quality & payout
Operating cash flow / net income0.20x
Accruals ratio-192.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20162016-12-31 | FY20152015-12-31 | FY20142014-12-31 | FY20132013-12-31 | FY20122012-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $313,229 | $4,272 | $2,739 | $224 | — |
| Cost of revenue | $294,062 | $3,875 | $2,636 | $2,315 | — |
| Gross profit | $19,167 | $397 | -$20,726 | -$2,091 | — |
| R&D expense | — | $48 | $4,000 | — | — |
| SG&A expense | $51,838 | $114,820 | $16,298 | $39,497 | $5,767 |
| Operating income | -$86,647 | -$156,173 | -$545,216 | -$1.27M | -$361,423 |
| Interest expense | $323,796 | $120,028 | $109,631 | $168,862 | $37,655 |
| Pretax income | -$410,443 | -$266,064 | -$669,409 | -$1.46M | -$399,078 |
| Net income | -$410,443 | -$266,064 | -$669,409 | -$1.46M | -$399,078 |
| EPS (basic) | -0.15 | -0.14 | -0.99 | -4.91 | -0.05 |
| EPS (diluted) | — | — | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $20,542 | $2,055 | $4,871 | $711 | $1,076 |
| Receivables | $11,724 | $3,150 | — | — | — |
| Inventory | — | $8,370 | $0 | $24,879 | — |
| Current assets | $32,905 | $15,107 | $43,730 | $25,590 | $1,076 |
| Total assets | $33,145 | $15,407 | $44,030 | $25,590 | $207,676 |
| Current liabilities | $528,592 | $403,226 | $324,582 | $223,348 | $185,476 |
| Short-term debt | — | — | $169,923 | $78,715 | — |
| Total liabilities | $528,592 | $403,226 | $324,582 | $223,348 | $185,476 |
| Shareholders' equity | -$495,447 | -$387,819 | -$280,552 | -$197,758 | $22,200 |
| Shares outstanding | 3.31M | 2.45M | 1.31M | 377,456 | 10.11M |
| Cash flow statement | |||||
| Operating cash flow | -$39,263 | -$115,776 | -$135,352 | -$131,985 | -$83,691 |
| Investing cash flow | $250 | -$250 | — | — | — |
| Financing cash flow | $57,500 | $113,210 | $139,512 | $131,620 | $78,600 |
| Stock-based compensation | $1,875 | $32,775 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.